1,414 research outputs found
Supplementary Figure 7 from <sup>177</sup>Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
No full textSupplemental Figure 7: VAC treatment did not improve therapeutic efficacy of DOTA-EB-TATE in either low- or high-SSTR2 expressing tumors. (A) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated FTC133 (low-SSTR2-expressing) subcutaneous xenograft mice model. C-control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC-valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=9). Data are presented as mean{plus minus}SEM. (B) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated AR42J (high-SSTR2-expressing) subcutaneous xenograft mice model. C-control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC-valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=7). Data are presented as mean{plus minus}SEM.</p
Supplementary Figure 5 from <sup>177</sup>Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
No full textSupplemental figure 5: Decitabine (DEC) treatment did not improve the uptake of 86Y-DOTA-EB-TATE in the tumors of the mice models. (A) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and decitabine (DEC) treated FTC133 subcutaneous mice model. The bar graph shows no significant difference in the uptake of 86Y-DOTA-EB-TATE between the control (n=3) and DEC (n=3) treated mice. (B) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and DEC treated AR42J subcutaneous mice model. The bar graph shows no significant difference in the uptake of 86Y-DOTA-EB-TATE between the control (n=5) and DEC (n=3) treated mice. Tumors (Tu) are indicated by white arrows.</p
Supplementary Figure 4 from <sup>177</sup>Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
No full textSupplemental figure 4: VAC treatment did not improve the uptake of SST analogs in the tumors of the mice models. (A) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated FTC133 subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=5) and VAC (n=5) treated mice. The representative immunohistochemistry images show an increased cytoplasmic expression of SSTR2 in the tumors of the VAC treated mice in comparison to the tumors of the control mice (Supplemental Table 2). (B) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated FTC133 metastatic mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=8-12) and VAC (n=8-12) treated mice. The immunohistochemistry images show no difference in the expression of SSTR2 in the metastatic tumors of the control and VAC treated FTC133 mice (Supplemental Table 2). (C) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated TT subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=5) and VAC (n=5) treated mice. The representative immunohistochemistry images show no difference in the expression of SSTR2 within the tumors of the control and VAC treated mice (Supplemental Table 2). (D) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated AR42J subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=4) and VAC (n=5) treated mice. The representative immunohistochemistry images show an increased expression of SSTR2 in the tumors of the VAC treated mice in comparison to the tumors of the control mice (Supplemental Table 2). Tumors (Tu) and metastasis (Met) are indicated by white arrows. The SUV scales range from 0 to 3 for 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and 0 to 15 for 86Y-DOTA-EB-TATE. Data are presented as mean{plus minus}SD.</p
Supplementary Figure 6 from <sup>177</sup>Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
No full textSupplemental figure 6: Treatment with epigenetic modulators did not increase 86Y-DOTA-EB-TATE uptake within the tumor and normal tissues of the mice models. (A) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=5) and VAC treated (n=5) FTC133 subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; ***p<0.001, **p<0.01 w.r.t control tumor; ^^^p<0.001, ^^p<0.01, ^p<0.05 w.r.t VAC tumor. C-control; VAC- valproic acid. (B) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=4) and VAC treated (n=5) AR42J subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^^p<0.001 w.r.t VAC tumor. C-control; VAC- valproic acid. (C) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=3) and DEC treated (n=3) FTC133 subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^p<0.01, ^p<0.05 w.r.t DEC tumor. C-control; DEC- decitabine. (D) The bar graph shows quantification of 86Y-DOTA-EB-TATE in the tumor and normal tissues (liver, kidneys, spleen, heart, and lungs) of the control (n=5) and DEC treated (n=3) AR42J subcutaneous xenograft mice. p=NS (non-significant) w.r.t corresponding control mice tissues; **p<0.01, *p<0.05 w.r.t control tumor; ^^p<0.01, ^p<0.05 w.r.t DEC tumor. C-control; DEC- decitabine.</p
Supplementary Figure 8 from <sup>177</sup>Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
No full textSupplementary figure 8. Experimental design of mice studies. (A) Flow diagram depicts an experimental strategy for PET imaging with different SST analogs in tumor mice models. (B) Flow diagram depicts an experimental strategy for 177Lu-DOTA-EB-TATE therapy in mice models characterized by high- and low- SSTR2 expression and similar tumor growth rate. (C) Flow diagram depicts an experimental strategy involving treatment with different 177Lu-labeled SST analogs in a mice model characterized by high- SSTR2 expression.</p
Exhaled breath SARS-CoV-2 shedding patterns across variants of concern
No full textOBJECTIVES: We performed exhaled breath (EB) and nasopharyngeal (NP) quantitative polymerase chain reaction (qPCR) and NP rapid antigen testing (NP RAT) of SARS-CoV-2 infections with different variants. METHODS: We included immuno-naïve alpha-infected (n = 11) and partly boosted omicron-infected patients (n = 8) as high-risk contacts. We compared peak NP and EB qPCR cycle time (ct) values between cohorts (Wilcoxon-Mann-Whitney test). Test positivity was compared for three infection phases using Cochran Q test. RESULTS: Peak median NP ct was 11.5 (interquartile range [IQR] 10.1-12.1) for alpha and 12.2 (IQR 11.1-15.3) for omicron infections. Peak median EB ct was 25.2 (IQR 24.5-26.9) and 28.3 (IQR 26.4-30.8) for alpha and omicron infections, respectively. Distributions did not differ between cohorts for NP (P = 0.19) or EB (P = 0.09). SARS-CoV-2 shedding peaked on day 1 in EB (confidence interval [CI] 0.0 - 4.5) and day 3 in NP (CI 1.5 - 6.0). EB qPCR positivity equaled NP qPCR positivity on D0-D1 (P = 0.44) and D2-D6 (P = 1.0). It superseded NP RAT positivity on D0-D1 (P = 0.003) and D2-D6 (P = 0.008). It was inferior to both on D7-D10 (P < 0.001). CONCLUSION: Peak EB and nasopharynx shedding were comparable across variants. EB qPCR positivity matched NP qPCR and superseded NP RAT in the first week of infection
AUTHOR CONTRIBUTION
No full textConception or design of the study: Silva AC, Silva LG, Souza ARS, Martins, AKL, Gomes EB. Data collection: Silva AC, Silva LG, Souza ARS. Analysis and interpretation of the data: Silva AC, Silva LG, Souza ARS. Writing of the article or critical review: Silva AC, Gomes EB. Final approval of the version to be published: Silva AC, Martins, AKL, Oliveira CJ, Alencar AMPG, Gomes EB
Supporting safe motherhood : a review of financial trends : summary
No full textAn estimated 500,000 women, 99 percent of them from the developing world, die each year from pregnancy-related causes. About three quarters of these deaths are the direct result of obstetrical complications -- hemorrhage, infection, toxemia, obstructed labor, and abortion (under primitive and illegal conditions). An estimated equivalent number of infants do not survive their mother's death. For surviving mothers, the consequences of pregnancy have a severe impact on health and family economics. The strategy for safe motherhood is based on two approaches. First, the encouragement of activities that indirectly improve maternal health. These include education, policies to improve women's rights and working conditions, health care and nutrition, transportation and communication systems, water and sanitation facilities, and increases in family income and food production. The second approach targets activities to reduce maternal deaths. These activities include reducing unwanted pregnancies through the provision of family planning services, and through national policies that recognize the importance of this issue. A second objective is to reduce the risks of pregnancy through providing community-based family planning and prenatal services to identify high-risk cases'adequate referral services for the complications of pregnancy, and communication and transport systems to support patient referral procedures.Health Monitoring&Evaluation,Health Systems Development&Reform,Gender and Health,Early Child and Children's Health,Agricultural Knowledge&Information Systems
AUTHOR CONTRIBUTION
No full textConception or design of the study: Silva AC, Silva LG, Souza ARS, Martins, AKL, Gomes EB. Data collection: Silva AC, Silva LG, Souza ARS. Analysis and interpretation of the data: Silva AC, Silva LG, Souza ARS. Writing of the article or critical review: Silva AC, Gomes EB. Final approval of the version to be published: Silva AC, Martins, AKL, Oliveira CJ, Alencar AMPG, Gomes EB
AUTHOR CONTRIBUTION
No full textConception or design of the study: Silva AC, Silva LG, Souza ARS, Martins, AKL, Gomes EB. Data collection: Silva AC, Silva LG, Souza ARS. Analysis and interpretation of the data: Silva AC, Silva LG, Souza ARS. Writing of the article or critical review: Silva AC, Gomes EB. Final approval of the version to be published: Silva AC, Martins, AKL, Oliveira CJ, Alencar AMPG, Gomes EB
- …
